Search Results for "Gemzar For Metastatic Melanoma"
Original Source: Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma
The purpose of this first-in-man study is to evaluate the safety of 188Re-PTI-6D2 in patients with metastatic melanoma. All patients will receive a tracer dose of 188Re-PTI-6D2 in order to provide information on how the monoclonal antibody is distributed throughout the body and to assess tumor targeting. No therapeutic dose of radiation will be given in the first study.
Matching Channels
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes....
Matching News
GSK submits melanoma drugs for regulatory approval
GlaxoSmithKline has submitted its two investigational melanoma drugs to regulators in both Europe and the US. The firm is seeking approval of its BRAF inhibitor dabrafenib and MEK inhibitor trametinib...
Melanoma Research Alliance awards $9.6 million in research grants
(Melanoma Research Alliance Foundation) The Melanoma Research Alliance, the largest private funder of melanoma research, today announced grant awards exceeding $9.6 million to 49 scientists at leading...
[Comment] Ipilimumab with fotemustine in metastatic melanoma
Ipilimumab—an antibody against cytotoxic T-lymphocyte-associated protein 4—was the first systemic treatment in unresectable metastatic melanoma to be proven to extend overall survival. No previous...
Potential Survival Predictor For Some Metastatic Melanoma Patients: CT And Serum LDH
Combining CT imaging findings with baseline serum lactate dehydrogenase levels is showing promise as a way to predict survival in patients with metastatic melanoma being treated with anti-angiogenic t...
Top-line final data from Provectus’ PV-10 phase 2 trial on metastatic melanoma
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that top-line final data from its phase 2 clinical trial of PV-10 for metastatic mela...
GSK submits marketing authorisation application for metastatic melanoma therapy
GlaxoSmithKline (GSK) has submitted marketing authorisation application, to the European Medicines Agency, for trametinib (MEK) as monotherapy and dabrafenib (BRAF)/MEK combination therapy in metastat...
Should high-dose interleukin-2 continue to be the treatment of choice for metastatic melanoma?
(Mary Ann Liebert, Inc./Genetic Engineering News) Administering high-doses of interleukin-2 has been the preferred treatment for patients with stage IV metastatic melanoma.
CT and serum LDH shows promise as survival predictor for some metastatic melanoma patients
Combining CT imaging findings with baseline serum lactate dehydrogenase levels is showing promise as a way to predict survival in patients with metastatic melanoma being treated with anti-angiogenic t...
Matching PubMed Articles
Transcriptional silencing of tissue factor pathway inhibitor 2 (TFPI2) occurs in several human tumors including melanoma. We investigated methylated TFPI2 as a biomarker of metastatic melanoma using q...
Alpha-interferon induced sarcoidosis mimicking metastatic melanoma.
Despite its modest potential benefit, alpha-interferon is one of the most frequently employed therapies for melanoma. With the increasing incidence of melanoma, a parallel increase in interferon use a...
CTGF is a therapeutic target for metastatic melanoma.
Metastatic melanoma remains a devastating disease with a 5-year survival rate of less than five percent. Despite recent advances in targeted therapies for melanoma, only a small percentage of melanoma...
Narrative Review: BRAF Opens the Door for Therapeutic Advances in Melanoma.
Patients with metastatic melanoma have a poor prognosis and limited treatment options. In about one half of analyzed patients with metastatic melanoma, a mutated signal transduction molecule has been...
Folliculotropic metastatic melanoma: a distinct variant of metastatic melanoma.
